ExpreS2ion Biotech Holding

Newsrelease Dec 12.

"ExpreS2ion’s patent and research partner publishes malaria vaccine breakthrough in Nature

ExpreS2ion Biotech Holding AB (“ExpreS2ion") announces the publication of the first visual image of the molecular ’key’ the deadliest malaria parasite uses to enter human blood cells in Nature. The publication was authored by an international team, including scientists from ExpreS2ion, led by the Walter and Eliza Hall Institute of Medical Research (“WEHI”). This breakthrough will contribute to the development of vaccines based on a patent co-owned equally by WEHI and ExpreS2ion.

By creating a visualisation of this molecular ’key’ for the very first time, scientists now have access to the previously missing information required to design a malaria vaccine that combats the prevalent Plasmodium falciparum parasite by ’locking it down’ so that it is unable to spread and infect blood cells throughout the body.

ExpreS2ion previously announced (PR 2017-04-06) the filing of a joint-patent for an improved blood-stage malaria vaccine together with WEHI. The Nature paper released today documents the scientific high quality of this collaboration and strengthens the parties’ joint effort to produce vaccines that targets the eradication of malaria.

“This is very exciting as the published ’key’ structure constitutes a milestone in the search and design of new, efficient blood stage malaria vaccines. As this target a $400 millon market and we have 50% ownership of vaccines developed under the patent collaboration, this also represent a substantial potential value and opportunity for us. We are proud that our ExpreS2 platform has contributed to this work and look forward to continue our fruitful research and patent collaboration with the acknowledged experts at WEHI.” says ExpreS2ion’s CEO Dr. Steen Klysner.

The study, involving Nobel Prize-winning technology, was led by Professor Alan Cowman and Dr. Wilson Wong at WEHI in a collaboration with the Howard Hughes Medical Institute’s Janelia Campus (US) and ExpreS2ion.

The malaria ‘key’ is a complex of three parasite proteins called Rh5, CyRPA and Ripr. The Ripr protein was produced and purified by ExpreS2ion using its ExpreS2 platform. The three proteins work together to unlock and enter the cell and the complex thereby constitutes a new and promising target for vaccine development.

Malaria

In WHO’s World Malaria Report newly issued in November 2018 it is estimated that there were 219 million cases of malaria in 2017. Malaria continues to claim the lives of more than 435,000 people each year, largely in Africa. Children under the age of 5 are especially vulnerable; and WHO estimates that every two minutes a child dies from this preventable disease. In 2017, an estimated US$ 3.1 billion was invested globally in malaria control and elimination efforts by governments of malaria endemic countries and international partners. The blood stage malaria market is estimated to translate into an amount of approximately 400 mio $ annually (Boston Consulting Group 2014). "


expres2ionbio.com/investor/international-press-releases/details/?id=28911C01682F46B4


Nature :   www.nature.com/articles/s41586-018-0779-6

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate at several key events in March and April, including ISBiotech, March 4-6, in Norfolk, VA, USA, Sedermeradagen, March 12, In Copenhagen, Denmark, and World Vaccine Congress, April 15-17, in Washington, DC, USA.


expres2ionbio.com/investor/international-press-releases/details/?id=845C11699EA9D843

"ExpreS2ion announces the publication of a proof of concept in animals for a new potential breakthrough malaria vaccine
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces the publication of a scientific article in Cellular Microbiology providing the first proof of concept in an animal model for a next generation malaria vaccine that is targeting a recently discovered molecular ’key’ that the deadly malaria parasite uses to enter human blood cells.

The publication was authored by an international team, including scientists from ExpreS2ion, led by the Walter and Eliza Hall Institute of Medical Research (“WEHI”). The proof of concept presented in the article provides documentation, which could contribute to the development of vaccines based on a patent co-owned by WEHI and ExpreS2ion.

“This is the first time this type of vaccine has been shown to work in an animal model. As such, it is an important step towards developing human vaccines that aim at eradicating malaria. It is particularly gratifying that the article has been published today on April 25, which is the WHO World Malaria Day” says ExpreS2ion’s CEO Dr. Steen Klysner.

The malaria ‘key’ was first described in a Nature article, published December 2018 from the group. It is a complex of three parasite proteins called Rh5, CyRPA and Ripr, where the three proteins work together to unlock and enter the cell. This central role in the infection of human blood cells makes the complex a new and promising target for vaccine development.

The article can be found at: onlinelibrary.wiley.com/doi/epdf/10.1111/cmi.13030

Malaria facts (WHO)

Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable, but never the less there were an estimated 219 million cases of malaria in 87 countries and the estimated number of deaths caused by malaria was 435,000 in 2017. See also “The World Malaria Day”: www.who.int/campaigns/world-malaria-day/world-malaria-day-2019 "

expres2ionbio.com/investor/international-press-releases/details/?id=383C7B9C171CE1FC

Newsrelease :

"ExpreS2ion licenses groundbreaking CRISPR/Cas9 gene editing technology from ERS Genomics

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces the signing of a non-exclusive license agreement with ERS Genomics, providing ExpreS2ion with the right to use and commercialise products, for its own use or together with customers or partners, based on the highly efficient CRISPR/Cas9 gene editing technology. This will enable the Company to offer a whole new range of solutions for the next generation of vaccines, immunotherapy and diagnostics."

expres2ionbio.com/investor/international-press-releases/details/?id=765C11F61B1D2540